Biophytis strengthens its senior management team and continues its expansion in
the United States
Paris (France), December 17, 2018, 7.30am - BIOPHYTIS (Euronext Growth Paris:
ALBPS), a biotechnology company developing drug candidates to reduce
disabilities caused by age-related and genetic degenerative diseases, announces
today the promotion of Jean-Christophe Montigny to the position of Chief
Operating Officer and the appointment of Daniel Schneiderman as Chief Financial
Officer based in the Company's U.S. office located in Cambridge, MA.
Since 2009, Mr. Jean-Christophe Montigny has been supervising the finance and
legal functions of Biophytis in France. As the newly appointed COO, Mr.
Montigny will continue to oversee his previous functions while ensuring
cross-functional management alongside Mr. Stanislas Veillet, Chief Executive
Officer of Biophytis.
As Chief Financial Officer based in the U.S., Mr. Daniel Schneiderman's roles
and responsibilities will include supervising the Company's capital markets,
investor relations, and certain financial and operational initiatives. He
brings over 16 years of capital raising, strategic advisory and operational
experience primarily with high-growth companies in the healthcare and life
sciences industries. Previously, Mr. Schneiderman served as Vice President of
Finance and Controller of MetaStat, Inc., a Boston-based precision medicine
company focused on developing novel anti-metastatic medications for patients
with aggressive cancer. Prior to joining MetaStat in 2012, Mr. Schneiderman was
Vice President of Investment Banking for Burnham Hill Partners where he worked
from 2004. Mr. Schneiderman began his investment banking career at H.C.
Wainwright & Co., Inc. as an Analyst. Mr. Schneiderman holds a Bachelor's
Degree in Economics from Tulane University.
Stanislas Veillet, CEO, stated: "We are pleased to welcome Mr. Schneiderman to
the Biophytis team. He brings a wealth of experience that will be invaluable as
we expand our presence in the U.S. to support increased financial, clinical and
commercialization efforts. We plan to continue building a strong clinical,
medical and regulatory infrastructure in Boston with additional key hires in
2018 and 2019, as we execute the clinical development of SARCONEOS through our
SARA-INT clinical phase 2b trial for the treatment of sarcopenia in both the
United States and Europe, as well as progress SARCONEOS through our MYODA study
program in Duchenne muscular dystrophy (DMD) and MACUNEOS through our MACA
study program in dry age-related macular degeneration (AMD)."
Mr. Schneiderman stated: "I am thrilled to join the leadership team at
Biophytis at such an exciting stage in its development. Based on both clinical
and preclinical data to date, I believe the Company's drug candidates offer
great potential to address significant unmet clinical needs. I look forward to
supporting the Company's growth initiatives and ultimately driving shareholder
Biophytis SA is a biotechnology company specializing in the development of drug
candidates to treat the disabilities caused by age-related degenerative
diseases. The Company's clinical stage pipeline is comprised of SARCONEOS, a
MAS receptor activator to preserve mobility in sarcopenia and Duchenne muscular
dystrophy patients, and MACUNEOS, a drug that binds PPAR to slow vision decline
in people with dry age-related macular degeneration (AMD). Biophytis
collaborates with expert scientists from several Sorbonne Université
institutes such as the Paris Seine Biology Institute, the Institute of Myology,
and the Vision Institute. The Company is based in Paris, France and in
BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS;
For more information please visit www.biophytis.com.
Follow us on Twitter @biophytis
BIOPHYTIS is eligible for the SMEs scheme
This press release contains certain forward-looking statements. Although the
Company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the Company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Listing Prospectus upon the
admission of Company's shares for trading on the regulated market Euronext
Growth of Euronext Paris filed with the AMF, which is available on the AMF
website (www.amf- france.org) or on BIOPHYTIS' website (www.biophytis.com).
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
BIOPHYTIS in any country. Items in this press release may contain
forward-looking statements involving risks and uncertainties. The Company's
actual results could differ substantially from those anticipated in these
statements owing to various risk factors which are described in the Company's
prospectus. This press release has been prepared in both French and English. In
the event of any differences between the two texts, the French language version